AstraZeneca (AZN) Tops Q4 EPS by 8c

AstraZeneca (NYSE: AZN) reported Q4 EPS of $1.21, $0.08 better than the analyst estimate of $1.13. Revenue for the quarter came in at $5.59 billion versus the consensus estimate of $5.57 billion.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.

You May Also Be Interested In

• FDA grants accelerated approval to AstraZeneca's camizestrant combo
• lululemon athletica (LULU) Tops Q2 EPS by $1.10, Cuts Guidance
• Samsara Inc (IOT) Tops Q2 EPS by 4c, Beats on Revenue; Offers Q3 Guidance